Modeling tumor response after combined administration of different immune-stimulatory agentss

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 432-442

  Parra Guillen, Zinnia P ^a   Berraondo, Pedro ^b   Ribba, Benjamin ^c   Trocóniz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INRIA Grenoble Rhne Alpes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE HUMAN PAPILLOMAVIRUS E7 FUSION PROTEIN; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL DESTRUCTION;

ADJUVANTS, IMMUNOLOGIC; ALGORITHMS; ANIMALS; CANCER VACCINES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS;

EID: 84882303482     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.206961     Document Type: Article

References (42)

1. Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, and Agliano A, et al. (2011) Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 187: 6130-6142.
2. Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, and Mitchison NA (2011) Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 60:1127-1135.
3. Beal SL and Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8:195-222.
4. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504.
5. Beal S, Sheiner L, Boeckmann A. NONMEM Users Guide (2006) 1989-2006
6. Beal S, Sheiner L, Boeckmann A (2006) NONMEM users guide [1989- 2006]. Beatty PL, Cascio S, and Lutz E (2011) Tumor immunology: basic and clinical advances. Cancer Res 71:4338-4343.
7. Berraondo P, Nouzé C, Préville X, Ladant D, and Leclerc C (2007) Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 67:8847-8855.
8. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, and Shin LK, et al. (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28: 4324-4332.
9. Bunimovich-Mendrazitsky S, Claude Gluckman J, and Chaskalovic J (2011) A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer. J Theor Biol 277:27-40.
10. Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, and Salphati L (2013) PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol 71:133-143.
11. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, and Singh H, et al. (2009) Improving the efficacy of cancer immunotherapy. Eur J Cancer 45:1424-1431.
12. Dougan M and Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
13. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GE, and Mahanty S, et al. (2010) Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS ONE 5:e8787.
14. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630-641.
15. Finn OJ (2012) Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 23 (suppl 8):viii6-9.
16. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, and Schneeweiss A, et al. (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61:353-362.
17. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, and Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD41CD251 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648.
18. Gorelik B, Ziv I, Shohat R, Wick M, Hankins WD, Sidransky D, and Agur Z (2008) Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 68:9033-9040.
19. Harrold JM, Straubinger RM, and Mager DE (2012) Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res 72:1632-1641.
20. Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, and Thurnher M (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54:663-670.
21. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, and Taniguchi T (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-1040.
22. Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, and Yi Q (2012) Cp G or IFN-A are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 61:561-571.
23. Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL, and Girard P (2007) Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 34:57-85.
24. Koch G, Walz A, Lahu G, and Schropp J (2009) Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36:179-197.
25. Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161-167.
26. Landrigan A, Wong MT, and Utz PJ (2011) CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD41 T cells through a TLR9- and MyD88- independent mechanism. J Immunol 187:3033-3043.
27. Lindbom L, Pihlgren P, and J onsson EN (2005) PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257.
28. Ludden TM, Beal SL, and Shei ner LB (1994) Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22:431-445.
29. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, and Sabzevari H (2005) Inhibition of CD4(1)251 T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868.
30. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, and Berraondo P (2011) Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 186: 807-815.
31. Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, and Khleif SN (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 41: 2977-2986.
32. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, and Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res 59:3128-3133.
33. Palucka K and Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-277.
34. Parra-Guillen ZP, Berraondo P, Grenier E, Ribba B, and Troconiz IF (2013) Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies. AAPS J 15:797-807.
35. Préville X, Ladant D, Timmerman B, and Leclerc C (2005) Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 65:641-649.
36. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, and Poggesi I (2007) Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43:1862-1868.
37. Rocchetti M, Del Bene F, Germani M, Fiorentini F, Poggesi I, Pesenti E, Magni P, and De Nicolao G (2009) Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach. Eur J Cancer 45:3336-3346.
38. Rosenberg SA, Yang JC, and Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915.
39. Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, and Nabors GS, et al. (2011) Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29:6313-6320.
40. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, and Romero P (2005) Rapid and strong human CD81 T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739-746.
41. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, and Mendrzyk R, et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254-1261.
42. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, and Hop CE, et al. (2012) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18:3846-3855.